Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07124013) titled 'A Study of Olomorasib (LY3537982) in Healthy Japanese Participants' on Aug. 13.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: None (Open Label).
Primary Sponsor: Eli Lilly and Company
Condition:
Healthy
Intervention:
Drug: Olomorasib
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 2025
Target Sample Size: 188
Countries of Recruitment:
Japan
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07124013
Published by HT Digital Content Services with permission...